Company Profile

DISHMAN CARBOGEN AMCIS LTD.

NSE : DCALBSE : 540701ISIN CODE : INE385W01011Industry : Pharmaceuticals & DrugsHouse : Dishman Pharma
BSE178.10-1.35 (-0.75 % )
PREV CLOSE (Rs.) 179.45
OPEN PRICE (Rs.) 183.90
BID PRICE (QTY) 178.10 (499 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 1836
TODAY'S LOW / HIGH (Rs.)175.00 183.90
52 WK LOW / HIGH (Rs.)173.35 314.65
NSE179.35 0.6 (+0.34 % )
PREV CLOSE(Rs.) 178.75
OPEN PRICE (Rs.) 177.50
BID PRICE (QTY) 179.35 (317 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 55602
TODAY'S LOW / HIGH(Rs.) 175.00 180.20
52 WK LOW / HIGH (Rs.)174.4 314.8

Smart Quotes

1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Trade Value (Rs. in Lacs) 3.25877
Dividend Yield(%)
TTM EPS (Rs.)
P/E Ratio
Book Value (Rs.)
Face Value (Rs.)
MCap (Rs. in Mn)
Price/Earning (TTM)
Price/Sales (TTM)
Price/Book (MRQ)
PAT Margin (%) 7.81
ROCE (%) 1.83
Incorporation Year : 2007

Management Info :

Janmejay R Vyas - Chairman Janmejay R Vyas - Managing Director

Registered Office :

Address : Bhadr- Raj Chambers,Swastik Cross Roads,Navrangpura,
Ahmedabad,
Gujarat-380009

Phone : 02717 420102

Registrar's Details : Link Intime India Pvt Ltd.
C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai
Listing : BSE, NSE
NEWS More
02Aug08-02-2019$Dishman Carbogen Amcis’ arm completes USFDA pre-approval inspection at Switzerland site Dishman Carbogen Amcis’ ar

Dishman Carbogen Amcis’ wholly owned subsidiary -- Carbogen Amcis AG's manufacturing site in Neuland, Switzerland, has successfully completed a U.S. Food and Drug Administration (USFDA) pre-approval inspection. The inspection was concluded with no Form 483's filed, thus confirming that no critical or major observation was raised during the inspection. The auditor will recommend the approval of API for which the audit was conducted.

The Hunzenschwil facility is one of Carbogen Amcis AG's four sites to offer development and manufacturing facilities for highly potent compounds. It manufactures products according to cGMP standards and is routinely inspected by Swissmedic, the FDA and external customers.

Dishman Carbogen Amcis provides innovative solutions for the development and supply of drug substances and drug products to the pharmaceutical and biopharmaceutical industries.

Dishman Carbogen Amcis’ wholly owned subsidiary -- Carbogen A..
02Aug08-02-2019$Dishman Carbogen Amcis rises as its arm completes USFDA pre-approval inspection at Switzerland site Dishman Carbogen Amcis rises

Dishman Carbogen Amcis is currently trading at Rs. 207.60, up by 0.55 points or 0.27% from its previous closing of Rs. 207.05 on the BSE.

The scrip opened at Rs. 209.40 and has touched a high and low of Rs. 209.60 and Rs. 206.15 respectively. So far 1045 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 314.65 on 03-Sep-2018 and a 52 week low of Rs. 180.35 on 26-Feb-2019.

Last one week high and low of the scrip stood at Rs. 218.30 and Rs. 197.00 respectively. The current market cap of the company is Rs. 3350.55 crore.

The promoters holding in the company stood at 61.40%, while Institutions and Non-Institutions held 20.99% and 17.61% respectively.

Dishman Carbogen Amcis’ wholly owned subsidiary -- Carbogen Amcis AG's manufacturing site in Neuland, Switzerland, has successfully completed a U.S. Food and Drug Administration (USFDA) pre-approval inspection. The inspection was concluded with no Form 483's filed, thus confirming that no critical or major observation was raised during the inspection. The auditor will recommend the approval of API for which the audit was conducted.

The Hunzenschwil facility is one of Carbogen Amcis AG's four sites to offer development and manufacturing facilities for highly potent compounds. It manufactures products according to cGMP standards and is routinely inspected by Swissmedic, the FDA and external customers.

Dishman Carbogen Amcis provides innovative solutions for the development and supply of drug substances and drug products to the pharmaceutical and biopharmaceutical industries.


Dishman Carbogen Amcis is currently trading at Rs. 207.60, up b..
22Jul07-22-2019$ Shareholding for the Period Ended June 30, 2019 Shareholding for the Period
Dishman Carbogen Amcis Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2019. For more details, kindly Click here
Dishman Carbogen Amcis Ltd has submitted to BSE the Shareholdin..
02May05-02-2019$Dishman Carbogen Amcis informs about board meeting Dishman Carbogen Amcis infor

Dishman Carbogen Amcis has informed that the meeting of the Board of Directors of the Company will be held on May 08, 2019, to consider, take on record and approve the Audited Financial Results of the Company for the quarter and year ended on March 31, 2019 and to consider and recommend Final Dividend on equity shares of the Company, if any. In view of the same and pursuant to the Code of Conduct to Regulate, Monitor and Report Trading by Designated Person(s) of the Company, the Trading Window for dealing in Securities by Designated Persons and their immediate relative(s) has been closed from April 03, 2019 to May 10, 2019. It is pertaining to note that the Company has made necessary disclosure regarding closure of Trading Window on April 03, 2019 to the Stock Exchanges.

The above information is a part of company’s filings submitted to BSE.

Dishman Carbogen Amcis has informed that the meeting of the Boa..
30Apr04-30-2019$Dishman Carbogen Amcis receives EIR from USFDA for Naroda facility Dishman Carbogen Amcis recei

Dishman Carbogen Amcis has received the Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for Naroda facility. Thus, the Company's facilities in Bavla and Naroda in India, multiple facilities in Switzerland and the Netherlands continue to be approved by the USFDA.

Earlier, USFDA had successfully inspected the company’s Naroda facility in February, 2019.

Dishman Carbogen Amcis provides innovative solutions for the development and supply of drug substances and drug products to the pharmaceutical and biopharmaceutical industries.

Dishman Carbogen Amcis has received the Establishment Inspectio..
Financials More
Rs. in Millions
QTR Jun 19 ANNUAL 19
Net Profit35.5560.1
Gross Profit 52.6 817.3
Operating Profit 505.22654.7
Net Sales 1334.15494.8
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group More
Dr. Reddys Lab (BSE)
 2554.90 (1.77%)
M.Cap ( in Cr)
42440.42
Astrazeneca Pharma I (BSE)
 1774.20 (2.41%)
M.Cap ( in Cr)
4435.50
Jenburkt Pharma (BSE)
 451.90 (6.33%)
M.Cap ( in Cr)
207.39
Alkem Laboratories (BSE)
 1768.85 (1.27%)
M.Cap ( in Cr)
21149.26
Everest Organics (BSE)
 179.15 (11.97%)
M.Cap ( in Cr)
143.32
Shareholding Pattern More
PROMOTERS 61.4 %
NON-INSTITUTION 17.61 %
MUTUAL FUNDS/UTI 11.95 %
FI/BANKS/INSURANCE 0.15 %
GOVERNMENT 0 %
FII 0 %
F & O Quotes